- Home
- HSII vs NNNN Comparison
HSII vs NNNN Comparison
Compare HSII & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HSII | NNNN |
|---|---|---|
| Founded | 1953 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 1999 | 2025 |
Fundamental Metrics
Financial Performance| Metric | HSII | NNNN |
|---|---|---|
| Price | $59.01 | $28.31 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $57.50 | N/A |
| AVG Volume (30 Days) | ★ 430.9K | 26.9K |
| Earning Date | 11-03-2025 | 04-28-2026 |
| Dividend Yield | ★ 1.02% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.73 | 0.06 |
| Revenue | ★ $1,199,854,000.00 | $8,185,146.00 |
| Revenue This Year | $13.60 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $34.12 | $534.57 |
| Revenue Growth | 11.56 | ★ 21.95 |
| 52 Week Low | $36.87 | $5.18 |
| 52 Week High | $59.05 | $55.65 |
Technical Indicators
Market Signals| Indicator | HSII | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 77.94 | 50.86 |
| Support Level | $58.84 | $26.89 |
| Resistance Level | $59.05 | $44.73 |
| Average True Range (ATR) | 0.09 | 5.91 |
| MACD | -0.11 | 0.18 |
| Stochastic Oscillator | 89.74 | 38.01 |
Price Performance
Historical ComparisonAbout HSII Heidrick & Struggles International Inc.
Heidrick & Struggles International Inc is a leadership advisory firm providing executive search and consulting services to businesses and business leaders world wide. The company's operating segments include the executive search business which operates in the Americas; Europe; Asia Pacific and On-Demand Talent and Heidrick Consulting. It generates maximum revenue from the Americas.
About NNNN Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.